Monte Rosa Therapeutics, Inc. (GLUE) DCF Valuation

Monte Rosa Therapeutics, Inc. (GLUE) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Monte Rosa Therapeutics, Inc. (GLUE) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Enhance your investment strategies with the Monte Rosa Therapeutics, Inc. (GLUE) DCF Calculator! Explore actual financial data for Monte Rosa, adjust growth projections and expenses, and instantly observe how modifications affect the intrinsic value of (GLUE).


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -7.7 -27.5 -70.8 -99.9 -137.1 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .1 .5 2.1 8.6 6.2 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -7.7 -28.0 -72.9 -108.5 -143.3 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 6.0 41.7 346.1 262.8 232.4 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 7.7 .5
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 1.0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 3.2 7.1 6.6 7.9 11.2 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -1.4 -3.4 -9.7 -12.9 -19.0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % -0.25034 -0.25034 -0.25034 -0.25034 -0.25034 -0.25034 -0.25034 -0.25034 -0.25034 -0.25034
EBITAT -8.0 -28.2 -70.9 -104.6 -143.7 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -6.1 -27.1 -79.0 -116.3 -145.1 -10.6 .0 .0 .0 .0
WACC, % 9.9 9.9 9.88 9.88 9.9 9.89 9.89 9.89 9.89 9.89
PV UFCF
SUM PV UFCF -9.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -10
Net Debt -82
Equity Value 72
Diluted Shares Outstanding, MM 51
Equity Value Per Share 1.41

What You Will Get

  • Real GLUE Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Dynamic Calculations: Intrinsic value and NPV are computed automatically.
  • Scenario Analysis: Evaluate various scenarios to assess Monte Rosa Therapeutics' future performance.
  • User-Friendly Design: Designed for professionals while remaining approachable for newcomers.

Key Features

  • Comprehensive Data Set: Monte Rosa’s historical financial statements and detailed projections.
  • Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Insights: Monitor Monte Rosa’s intrinsic value recalculating instantly.
  • Intuitive Visualizations: Dashboard graphs illustrate valuation outcomes and essential metrics.
  • Designed for Precision: A robust tool for analysts, investors, and finance professionals.

How It Works

  • Step 1: Download the prebuilt Excel template with Monte Rosa Therapeutics’ data included.
  • Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
  • Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view recalculated results, including Monte Rosa Therapeutics’ intrinsic value.
  • Step 5: Make informed investment decisions or generate reports using the outputs.

Why Choose This Calculator for Monte Rosa Therapeutics, Inc. (GLUE)?

  • User-Friendly Interface: Perfect for both newcomers and seasoned professionals.
  • Customizable Inputs: Adjust parameters easily to suit your financial analysis needs.
  • Real-Time Insights: Observe immediate updates to Monte Rosa's valuation as you tweak inputs.
  • Preloaded Data: Comes equipped with Monte Rosa's latest financial information for swift evaluations.
  • Preferred by Experts: A go-to tool for investors and analysts seeking to make knowledgeable choices.

Who Should Use Monte Rosa Therapeutics, Inc. (GLUE)?

  • Investors: Make informed decisions with insights from a cutting-edge biotechnology company.
  • Biotech Analysts: Enhance your analysis with comprehensive data on innovative therapeutic solutions.
  • Healthcare Consultants: Quickly tailor information for client discussions or strategic reports.
  • Life Sciences Enthusiasts: Expand your knowledge of drug development processes and market trends.
  • Educators and Students: Utilize it as a valuable resource in biotechnology and pharmaceutical studies.

What the Template Contains

  • Pre-Filled DCF Model: Monte Rosa Therapeutics’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Monte Rosa Therapeutics’ profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.